Metabolic Tumor Volume Metrics in Lymphoma.

Although visual assessment using the Deauville criteria is strongly recommended by guidelines for treatment response monitoring in all FDG-avid lymphoma histologies, the high rate of false-positives and concerns about interobserver variability have motivated the development of quantitative tools to facilitate objective measurement of tumor response in both routine and clinical trial settings. Imaging studies using functional quantitative measures play a significant role in profiling oncologic processes. These quantitative metrics allow for objective end points in multicenter clinical trials. However, the standardization of imaging procedures including image acquisition parameters, reconstruction and analytic measures, and validation of these methods are essential to enable an individualized treatment approach. A robust quality control program associated with the inclusion of proper scanner calibration, cross-calibration with dose calibrators and across other scanners is required for accurate quantitative measurements. In this section, we will review the technical and methodological considerations related to PET-derived quantitative metrics and the relevant published data to emphasize the potential value of these metrics in the prediction of patient prognosis in lymphoma.

[1]  Xiaoping Zhou,et al.  Prognostic value of total lesion glycolysis of baseline 18F-fluorodeoxyglucose positron emission tomography/computed tomography in diffuse large B-cell lymphoma , 2016, Oncotarget.

[2]  Piernicola Pedicini,et al.  F‐18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B‐cell lymphoma , 2014, European journal of haematology.

[3]  Deborah A. Bowen,et al.  Use of positron emission tomography-computed tomography in the management of patients with chronic lymphocytic leukemia/small lymphocytic lymphoma , 2014, Leukemia & lymphoma.

[4]  E. Malek,et al.  Metabolic tumor volume on interim PET is a better predictor of outcome in diffuse large B-cell lymphoma than semiquantitative methods , 2015, Blood Cancer Journal.

[5]  J. Briones,et al.  PET/CT Assessment of Follicular Lymphoma and High Grade B Cell Lymphoma - Good Correlation with Clinical and Histological Features at Diagnosis. , 2015, Advances in clinical and experimental medicine : official organ Wroclaw Medical University.

[6]  A. Zelenetz,et al.  Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in Advanced-stage diffuse large B-Cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Eric J. W. Visser,et al.  FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0 , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[8]  Adriaan A. Lammertsma,et al.  Effects of ROI definition and reconstruction method on quantitative outcome and applicability in a response monitoring trial , 2005, European Journal of Nuclear Medicine and Molecular Imaging.

[9]  R. Foà,et al.  Diagnostic and prognostic role of PET/CT in patients with chronic lymphocytic leukemia and progressive disease , 2015, Leukemia.

[10]  P. Christian,et al.  Quantitative PET/CT Scanner Performance Characterization Based Upon the Society of Nuclear Medicine and Molecular Imaging Clinical Trials Network Oncology Clinical Simulator Phantom , 2015, The Journal of Nuclear Medicine.

[11]  Utility of baseline 18FDG-PET/CT functional parameters in defining prognosis of primary mediastinal (thymic) large B-cell lymphoma. , 2015, Blood.

[12]  D. Hasenclever,et al.  qPET – a quantitative extension of the Deauville scale to assess response in interim FDG-PET scans in lymphoma , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[13]  U. Jaeger,et al.  Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study. , 2008, The Lancet. Oncology.

[14]  A. Tsimberidou,et al.  Richter syndrome , 2005, Cancer.

[15]  Ursula Nestle,et al.  Biological imaging in radiation therapy: role of positron emission tomography , 2009, Physics in medicine and biology.

[16]  D. Groheux,et al.  Variation of Liver SUV on 18FDG-PET/CT Studies in Women With Breast Cancer , 2013, Clinical nuclear medicine.

[17]  I. Steffen,et al.  FDG-PET Response Prediction in Pediatric Hodgkin’s Lymphoma: Impact of Metabolically Defined Tumor Volumes and Individualized SUV Measurements on the Positive Predictive Value , 2015, Cancers.

[18]  D. Mariano-Goulart,et al.  Association between textural and morphological tumor indices on baseline PET‐CT and early metabolic response on interim PET‐CT in bulky malignant lymphomas , 2017, Medical physics.

[19]  Claude Nahmias,et al.  Reproducibility of Standardized Uptake Value Measurements Determined by 18F-FDG PET in Malignant Tumors , 2008, Journal of Nuclear Medicine.

[20]  Sasa Mutic,et al.  Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer. , 2004, International journal of radiation oncology, biology, physics.

[21]  L. Ceriani,et al.  18F-FDG Uptake Changes in Liver and Mediastinum During Chemotherapy in Patients With Diffuse Large B-cell Lymphoma , 2012, Clinical nuclear medicine.

[22]  Di Yan,et al.  Defining a radiotherapy target with positron emission tomography. , 2002, International journal of radiation oncology, biology, physics.

[23]  E. Hindié,et al.  Variability of Hepatic 18F-FDG Uptake at Interim PET in Patients With Hodgkin Lymphoma , 2015, Clinical nuclear medicine.

[24]  Xiaodong Wu,et al.  Comparative study with new accuracy metrics for target volume contouring in PET image guided radiation therapy. , 2012, IEEE transactions on medical imaging.

[25]  G. Salles,et al.  An 18F-FDG-PET maximum standardized uptake value > 10 represents a novel valid marker for discerning Richter’s Syndrome , 2016, Leukemia & lymphoma.

[26]  P. Lambin,et al.  Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach , 2014, Nature Communications.

[27]  E. Palmer,et al.  Baseline total lesion glycolysis measured with (18)F-FDG PET/CT as a predictor of progression-free survival in diffuse large B-cell lymphoma: a pilot study. , 2013, American journal of nuclear medicine and molecular imaging.

[28]  Jan-Jakob Sonke,et al.  The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer. , 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[29]  F. Brunotte,et al.  Interim 18F-FDG PET SUVmax Reduction Is Superior to Visual Analysis in Predicting Outcome Early in Hodgkin Lymphoma Patients , 2014, The Journal of Nuclear Medicine.

[30]  Robert Jeraj,et al.  Impact of Different Standardized Uptake Value Measures on PET-Based Quantification of Treatment Response , 2013, The Journal of Nuclear Medicine.

[31]  Yanhui Xie,et al.  Predictive value of F-18 FDG PET/CT quantization parameters for progression-free survival in patients with diffuse large B-cell lymphoma , 2015, Hematology.

[32]  Y. Erdi,et al.  Schöder H, Noy A, Gönen M, et al. Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol. 23: 4643-4651 , 2005 .

[33]  Stuart A. Taylor,et al.  Quantitative diffusion weighted MRI: a functional biomarker of nodal disease in Hodgkin lymphoma? , 2011, Cancer biomarkers : section A of Disease markers.

[34]  Joel S. Karp,et al.  Qualification of PET Scanners for Use in Multicenter Cancer Clinical Trials: The American College of Radiology Imaging Network Experience , 2009, Journal of Nuclear Medicine.

[35]  M. Czuczman,et al.  In vivo treatment sensitivity testing with positron emission tomography/computed tomography after one cycle of chemotherapy for Hodgkin lymphoma. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  W. Oyen,et al.  FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0 , 2009, European Journal of Nuclear Medicine and Molecular Imaging.

[37]  H. Jacobsson,et al.  The relation between the blood glucose level and the FDG uptake of tissues at normal PET examinations , 2013, EJNMMI Research.

[38]  Joshua J Gagne,et al.  Innovative research methods for studying treatments for rare diseases: methodological review , 2014, BMJ : British Medical Journal.

[39]  R. Boellaard,et al.  18F-FDG or 3′-Deoxy-3′-18F-Fluorothymidine to Detect Transformation of Follicular Lymphoma , 2015, The Journal of Nuclear Medicine.

[40]  Ronald Boellaard,et al.  Impact of [18F]FDG PET imaging parameters on automatic tumour delineation: need for improved tumour delineation methodology , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[41]  Habib Zaidi,et al.  A novel fuzzy C-means algorithm for unsupervised heterogeneous tumor quantification in PET. , 2010, Medical physics.

[42]  R. Boellaard,et al.  Repeatability of 18F-FDG Uptake Measurements in Tumors: A Metaanalysis , 2012, The Journal of Nuclear Medicine.

[43]  M Tubiana,et al.  Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  Yan Liu,et al.  Predictive value of F-18 FDG PET/CT quantization parameters in diffuse large B cell lymphoma: a meta-analysis with 702 participants , 2014, Medical Oncology.

[45]  Ho-Jin Shin,et al.  Prognostic value of metabolic tumor volume on PET / CT in primary gastrointestinal diffuse large B cell lymphoma , 2012, Cancer science.

[46]  M. Matoba,et al.  Diagnostic Performance of Diffusion-Weighted Imaging for Multiple Hilar and Mediastinal Lymph Nodes with FDG Accumulation. , 2015, Asian Pacific journal of cancer prevention : APJCP.

[47]  P. Christian,et al.  Use of a precision fillable clinical simulator phantom for PET/CT scanner validation in multi-center clinical trials: The SNM Clinical Trials Network (CTN) Program , 2012 .

[48]  Pierre Vera,et al.  Molecular Profile and FDG-PET/CT Total Metabolic Tumor Volume Improve Risk Classification at Diagnosis for Patients with Diffuse Large B-Cell Lymphoma , 2015, Clinical Cancer Research.

[49]  G Loi,et al.  Threshold segmentation for PET target volume delineation in radiation treatment planning: the role of target-to-background ratio and target size. , 2008, Medical physics.

[50]  G. Salles,et al.  Baseline Metabolic Tumor Volume Predicts Outcome in High-Tumor-Burden Follicular Lymphoma: A Pooled Analysis of Three Multicenter Studies. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  C. Copie-Bergman,et al.  Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[52]  C. Wassberg,et al.  Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes. , 2015, Clinical radiology.

[53]  H. Tilly,et al.  Pretherapy metabolic tumour volume is an independent predictor of outcome in patients with diffuse large B-cell lymphoma , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[54]  M. Hatt,et al.  Intratumor Heterogeneity Characterized by Textural Features on Baseline 18F-FDG PET Images Predicts Response to Concomitant Radiochemotherapy in Esophageal Cancer , 2011, The Journal of Nuclear Medicine.

[55]  Giovanni Martinelli,et al.  Follicular lymphoma international prognostic index 2: a new prognostic index for follicular lymphoma developed by the international follicular lymphoma prognostic factor project. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[56]  R. Boellaard Methodological aspects of multicenter studies with quantitative PET. , 2011, Methods in molecular biology.

[57]  Rakesh Kumar,et al.  Pediatric lymphoma: metabolic tumor burden as a quantitative index for treatment response evaluation , 2011, Annals of Nuclear Medicine.

[58]  I. Buvat,et al.  Comparative Assessment of Methods for Estimating Tumor Volume and Standardized Uptake Value in 18F-FDG PET , 2010, Journal of Nuclear Medicine.

[59]  R. Boellaard,et al.  Repeatability of 18F-FDG PET in a Multicenter Phase I Study of Patients with Advanced Gastrointestinal Malignancies , 2009, Journal of Nuclear Medicine.

[60]  K. Ishii,et al.  Heterogeneity of intratumoral 111In-ibritumomab tiuxetan and 18F-FDG distribution in association with therapeutic response in radioimmunotherapy for B-cell non-Hodgkin’s lymphoma , 2015, EJNMMI Research.

[61]  Y. Erdi,et al.  Intensity of 18fluorodeoxyglucose uptake in positron emission tomography distinguishes between indolent and aggressive non-Hodgkin's lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  P. Lambin,et al.  Stability of FDG-PET Radiomics features: An integrated analysis of test-retest and inter-observer variability , 2013, Acta oncologica.

[63]  Patrick Granton,et al.  Radiomics: extracting more information from medical images using advanced feature analysis. , 2012, European journal of cancer.

[64]  Stephane Chauvie,et al.  International Validation Study for Interim PET in ABVD-Treated, Advanced-Stage Hodgkin Lymphoma: Interpretation Criteria and Concordance Rate Among Reviewers , 2013, The Journal of Nuclear Medicine.

[65]  E. Noordijk,et al.  Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: concepts and guidelines. , 2006, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[66]  J. Yahalom,et al.  Transformation in the use of radiation therapy of Hodgkin lymphoma: New concepts and indications lead to modern field design and are assisted by PET imaging and intensity modulated radiation therapy (IMRT) , 2005, European journal of haematology. Supplementum.

[67]  Bruce D Cheson,et al.  Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[68]  R. Wahl,et al.  From RECIST to PERCIST: Evolving Considerations for PET Response Criteria in Solid Tumors , 2009, Journal of Nuclear Medicine.

[69]  P. Moreau,et al.  Investigation of FDG-PET/CT imaging to guide biopsies in the detection of histological transformation of indolent lymphoma , 2008, Haematologica.

[70]  A. Ng,et al.  Modern radiation therapy for nodal non-Hodgkin lymphoma-target definition and dose guidelines from the International Lymphoma Radiation Oncology Group. , 2014, International journal of radiation oncology, biology, physics.

[71]  T. Kwee,et al.  Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole‐body volumetric–metabolic FDG‐PET/CT metrics in diffuse large B‐cell lymphoma , 2015, European journal of haematology.

[72]  L. Specht,et al.  Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake , 2006, Hematological oncology.

[73]  E. Laffon,et al.  On the Cutoff of Baseline Total Metabolic Tumor Volume in High-Tumor-Burden Follicular Lymphoma. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  Martin A Lodge,et al.  Noise Considerations for PET Quantification Using Maximum and Peak Standardized Uptake Value , 2012, The Journal of Nuclear Medicine.

[75]  Z. Estrov,et al.  Correlation between FDG/PET, histology, characteristics, and survival in 332 patients with chronic lymphoid leukemia. , 2014, Blood.

[76]  Andrew Homb,et al.  18F-FDG PET/CT for Early Response Assessment in Diffuse Large B-Cell Lymphoma: Poor Predictive Value of International Harmonization Project Interpretation , 2011, The Journal of Nuclear Medicine.

[77]  S. Barrington,et al.  Combination of baseline metabolic tumour volume and early response on PET/CT improves progression-free survival prediction in DLBCL , 2016, European Journal of Nuclear Medicine and Molecular Imaging.

[78]  A. Rahmouni,et al.  Prognostic Value of Interim 18F-FDG PET in Patients with Diffuse Large B-Cell Lymphoma: SUV-Based Assessment at 4 Cycles of Chemotherapy , 2009, Journal of Nuclear Medicine.

[79]  Seong-Jang Kim,et al.  Clinical significance of metabolic tumor volume by PET/CT in stages II and III of diffuse large B cell lymphoma without extranodal site involvement , 2011, Annals of Hematology.

[80]  H. Tilly,et al.  An international confirmatory study of the prognostic value of early PET/CT in diffuse large B-cell lymphoma: comparison between Deauville criteria and ΔSUVmax , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[81]  I. Steffen,et al.  SUV‐measurements and patient‐specific corrections in pediatric Hodgkin‐lymphoma: Is there a benefit for PPV in early response assessment by FDG‐PET? , 2012, Pediatric blood & cancer.

[82]  P. Gobbi,et al.  The clinical value of tumor burden at diagnosis in Hodgkin lymphoma , 2004, Cancer.

[83]  Paul Kinahan,et al.  Evaluation of strategies towards harmonization of FDG PET/CT studies in multicentre trials: comparison of scanner validation phantoms and data analysis procedures , 2013, European Journal of Nuclear Medicine and Molecular Imaging.

[84]  John L. Humm,et al.  Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. , 1999, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

[85]  R. Wahl,et al.  18F-FDG PET/CT for Monitoring the Response of Lymphoma to Radioimmunotherapy , 2008, Journal of Nuclear Medicine.

[86]  I. Steffen,et al.  Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[87]  M. Goodman,et al.  Role of FDG-PET in the definition of involved-field radiation therapy and management for pediatric Hodgkin's lymphoma. , 2011, International journal of radiation oncology, biology, physics.

[88]  Mithat Gönen,et al.  [¹⁸F]FDG-positron emission tomography coregistration with computed tomography scans for radiation treatment planning of lymphoma and hematologic malignancies. , 2011, International journal of radiation oncology, biology, physics.

[89]  Jan-Jakob Sonke,et al.  Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcomE (ARTFORCE); a randomized controlled phase II trial for individualized treatment of head and neck cancer , 2013, BMC Cancer.

[90]  Dimitris Visvikis,et al.  Reproducibility of 18F-FDG and 3′-Deoxy-3′-18F-Fluorothymidine PET Tumor Volume Measurements , 2010, The Journal of Nuclear Medicine.

[91]  S. Ferrero,et al.  Interim 18-FDG-PET/CT failed to predict the outcome in diffuse large B-cell lymphoma patients treated at the diagnosis with rituximab-CHOP. , 2012, Blood.

[92]  R. Munden,et al.  Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[93]  T. Mattfeldt,et al.  Molecular imaging of proliferation in malignant lymphoma. , 2006, Cancer research.

[94]  Charles F Hildebolt,et al.  Diffusion‐weighted MRI for staging and evaluation of response in diffuse large B‐cell lymphoma: a pilot study , 2014, NMR in biomedicine.

[95]  Assen S. Kirov,et al.  Pathology-validated PET image data sets and their role in PET segmentation , 2014, Clinical and Translational Imaging.

[96]  Vincent Grégoire,et al.  Clinical use of PET-CT data for radiotherapy planning: what are we looking for? , 2010, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[97]  Vicky Goh,et al.  Quantifying tumour heterogeneity in 18F-FDG PET/CT imaging by texture analysis , 2012, European Journal of Nuclear Medicine and Molecular Imaging.

[98]  P. Gobbi,et al.  Image-aided estimate of tumor burden in Hodgkin's disease: evidence of its primary prognostic importance. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[99]  R. Lhommel,et al.  Quantitative and qualitative analysis of metabolic response at interim positron emission tomography scan combined with International Prognostic Index is highly predictive of outcome in diffuse large B-cell lymphoma , 2014, Leukemia and Lymphoma.

[100]  D. Mollura,et al.  Predicting Future Morphological Changes of Lesions from Radiotracer Uptake in 18F-FDG-PET Images , 2013, PloS one.

[101]  Alexandre Cochet,et al.  Baseline metabolic tumour volume is an independent prognostic factor in Hodgkin lymphoma , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[102]  J. Armitage,et al.  A prognostic score for advanced Hodgkin's disease. International Prognostic Factors Project on Advanced Hodgkin's Disease. , 1998, The New England journal of medicine.

[103]  R. Boellaard,et al.  Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[104]  R. Gascoyne,et al.  An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. , 2014, Blood.

[105]  Dong Soo Lee,et al.  Total lesion glycolysis in positron emission tomography is a better predictor of outcome than the International Prognostic Index for patients with diffuse large B cell lymphoma , 2013, Cancer.

[106]  H. Eich,et al.  Involved-Node Radiotherapy in Early-Stage Hodgkin’s Lymphoma , 2008, Strahlentherapie und Onkologie.

[107]  A. Bhattacharya,et al.  Prognostic value of quantitative parameters derived on initial staging 18F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with high-grade non-Hodgkin’s lymphoma , 2012, Nuclear medicine communications.

[108]  R. Advani,et al.  Interim-treatment quantitative PET parameters predict progression and death among patients with hodgkin's disease , 2012, Radiation oncology.

[109]  Y. Oki,et al.  High maximum standard uptake value (SUVmax) on PET scan is associated with shorter survival in patients with diffuse large B cell lymphoma , 2011, International journal of hematology.

[110]  Y. Tamaki,et al.  Quality assurance of radiotherapy in a clinical trial for lymphoma: individual case review. , 2007, Anticancer research.

[111]  G. Baroni,et al.  Radiotherapy of Hodgkin and Non-Hodgkin Lymphoma , 2016, Technology in cancer research & treatment.

[112]  Anne Bol,et al.  Tri-dimensional automatic segmentation of PET volumes based on measured source-to-background ratios: influence of reconstruction algorithms. , 2003, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[113]  Habib Zaidi,et al.  PET-guided delineation of radiation therapy treatment volumes: a survey of image segmentation techniques , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[114]  K. Murase,et al.  Variability of lesion detectability and standardized uptake value according to the acquisition procedure and reconstruction among five PET scanners , 2008, Annals of nuclear medicine.

[115]  J. Choi,et al.  The impact of baseline and interim PET/CT parameters on clinical outcome in patients with diffuse large B cell lymphoma , 2012, American journal of hematology.

[116]  R. Fisher,et al.  Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[117]  Otto Muzik,et al.  Imaging proliferation in vivo with [F-18]FLT and positron emission tomography , 1998, Nature Medicine.

[118]  Andre Dekker,et al.  Radiomics: the process and the challenges. , 2012, Magnetic resonance imaging.

[119]  I. Buvat,et al.  Partial-Volume Effect in PET Tumor Imaging* , 2007, Journal of Nuclear Medicine.

[120]  Fréderic Duprez,et al.  Maximum tolerated dose in a phase I trial on adaptive dose painting by numbers for head and neck cancer. , 2011, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[121]  J. Radford,et al.  Assessment and significance of mediastinal bulk in Hodgkin's disease: comparison between computed tomography and chest radiography. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[122]  Steve Y. Cho,et al.  Use of standardized uptake value thresholding for target volume delineation in pediatric Hodgkin lymphoma. , 2015, Practical radiation oncology.

[123]  K. Herholz,et al.  Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group. , 1999, European journal of cancer.

[124]  Kyung Hoon Hwang,et al.  Prognostic Value of Metabolic Tumor Volume Estimated by 18 F-FDG Positron Emission Tomography/Computed Tomography in Patients with Diffuse Large B-Cell Lymphoma of Stage II or III Disease , 2014, Nuclear Medicine and Molecular Imaging.

[125]  C. Mamot,et al.  Final Results of a Prospective Evaluation of the Predictive Value of Interim Positron Emission Tomography in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP-14 (SAKK 38/07). , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[126]  R. Advani,et al.  Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology. , 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

[127]  C. Rübe,et al.  Comparison of different methods for delineation of 18F-FDG PET-positive tissue for target volume definition in radiotherapy of patients with non-Small cell lung cancer. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[128]  L. Sehn,et al.  Erratum: An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era (Blood (2014) 123:6 (837-842)) , 2014 .

[129]  Carole Lartizien,et al.  Computer-Aided Staging of Lymphoma Patients With FDG PET/CT Imaging Based on Textural Information , 2012, IEEE Journal of Biomedical and Health Informatics.

[130]  H. Eich,et al.  Modern radiation therapy for Hodgkin lymphoma: field and dose guidelines from the international lymphoma radiation oncology group (ILROG). , 2014, International journal of radiation oncology, biology, physics.

[131]  V. Grégoire,et al.  PET/CT imaging for target volume delineation in curative intent radiotherapy of non-small cell lung cancer: IAEA consensus report 2014. , 2015, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[132]  A. Moreau,et al.  18-F FDG-PET in the staging of lymphocyte-predominant Hodgkin’s disease , 2008, Haematologica.

[133]  Seong-Jang Kim,et al.  Metabolic tumor volume by positron emission tomography/computed tomography as a clinical parameter to determine therapeutic modality for early stage Hodgkin's lymphoma , 2013, Cancer science.

[134]  M. Gönen,et al.  The majority of transformed lymphomas have high standardized uptake values (SUVs) on positron emission tomography (PET) scanning similar to diffuse large B-cell lymphoma (DLBCL). , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[135]  M. Kersten,et al.  Relationship between pretreatment FDG-PET and diffusion-weighted MRI biomarkers in diffuse large B-cell lymphoma. , 2014, American journal of nuclear medicine and molecular imaging.

[136]  H. Holte,et al.  Diffusion-weighted MRI compared to FDG PET/CT for assessment of early treatment response in lymphoma , 2015, Acta radiologica.

[137]  F. Jardin,et al.  Does enhanced CT influence the biological GTV measurement on FDG-PET images? , 2013, Radiotherapy and Oncology.

[138]  R. Boellaard,et al.  Interim positron emission tomography scan in multi-center studies: optimization of visual and quantitative assessments , 2009, Leukemia & lymphoma.

[139]  G. Salles,et al.  Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. , 2017, Blood.

[140]  B. Coiffier,et al.  SUVmax reduction improves early prognosis value of interim positron emission tomography scans in diffuse large B-cell lymphoma. , 2011, Blood.